Misoprostol

Identification

Name
Misoprostol
Accession Number
DB00929
Description

Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.13,14,4,2,10 The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the strength and frequency of contractions and decrease cervical tone.3

Misoprostol was granted FDA approval on 27 December 1988.13

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 382.5341
Monoisotopic: 382.271924326
Chemical Formula
C22H38O5
Synonyms
  • Misoprostol
  • Misoprostolum

Pharmacology

Indication

Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients.13 Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers.14 Misoprostol is used off label for the management of miscarriages, prevention of post partum hemorrhage, and is also used alone or in combination with mifepristone in other countries for first trimester abortions.4,2,10

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Misoprostol is a prostaglandin E1 analog used to reduce the risk of NSAID induced gastric ulcers by reducing secretion of gastric acid from parietal cells.3,13,14 Misoprostol is also used to manage miscarriages and used alone or in combination with mifepristone for first trimester abortions.4,2,6 An oral dose of misoprostol has an 8 minute onset of action and a duration of action of approximately 2 hours, a sublingual dose has an 11 minute onset of action and a duration of action of approximately 3 hours, a vaginal dose has a 20 minute onset of action and a duration of action of approximately 4 hours, and a rectal dose has a 100 minute onset of action and a duration of action of approximately 4 hours.7

Mechanism of action

Misoprostol is a synthetic prostaglandin E1 analog that stimulates prostaglandin E1 receptors on parietal cells in the stomach to reduce gastric acid secretion.3 Mucus and bicarbonate secretion are also increased along with thickening of the mucosal bilayer so the mucosa can generate new cells.3

Misoprostol binds to smooth muscle cells in the uterine lining to increase the strength and frequency of contractions as well as degrade collagen and reduce cervical tone.3

TargetActionsOrganism
AProstaglandin E2 receptor EP3 subtype
agonist
Humans
AProstaglandin E2 receptor EP2 subtype
agonist
Humans
UProstaglandin E2 receptor EP4 subtype
agonist
Humans
AProstaglandin E2 receptor EP1 subtype
agonist
Humans
Absorption

For an 800µg oral dose of misoprostol, the AUC was 2.0192±0.8032h*ng/mL, the Cmax was 2.6830±1.2161ng/mL, and a tmax of 0.345±0.186h.5 For a 800µg sublingual dose of misoprostol, the AUC was 3.2094±1.0417h*ng/mL, the Cmax was 2.4391±1.1567ng/mL, and a tmax of 0.712±0.415h.5 For a 800µg buccal dose of misoprostol, the AUC was 2.0726±0.3578h*ng/mL, the Cmax was 1.3611±0.3436ng/mL, and a tmax of 1.308±0.624h.5

Volume of distribution

Data regarding the volume of distribution of misoprostol is scarce.

The apparent volume of distribution of the active metabolite of misoprostol was in subjects with normal renal function was 13.6±8.0L/kg, with mild renal impairment was 17.3±23.0L/kg, with moderate renal impairment was 14.3±6.8L/kg, and with end stage renal disease was 11.0±9.6L/kg.8

Protein binding

Misoprostol is <90% protein bound in serum.13,14 Its active metabolite, misoprostol acid, is 81-89% protein bound in serum.9

Metabolism

Misoprostol is de-esterified to its active metabolite, misoprostol acid, also known as SC-30695.1 This metabolite is further reduced to dinor and tetranor metabolites (SC-41411), a prostaglandin F1 (PGF1) analog of SC-41411, and a ω-16-carboxylic acid derivative.1 However, the majority of these metabolites are not well described in the literature.1

Hover over products below to view reaction partners

Route of elimination

As much as 73.2±4.6% of a radiolabelled oral dose of misoprostol is recovered in the urine.1,14

Half-life

The half life of an 800µg oral dose is 1.0401±0.5090h, for a sublingual dose is 0.8542±0.1170h, and for a buccal dose is 0.8365±0.1346h.5

Clearance

Because of the rapid de-esterification of misoprostol before or during absorption, it is usually undetectable in plasma.8 Misoprostol's active metabolite, misoprostol acid, has a total body clearance of 0.286L/kg/min.8 Subjects with mild renal impairment had a total body clearance of 0.226±0.073L/kg/min, subjects with moderate renal impairment had a total body clearance of 0.270±0.103L/kg/min, and subjects with end stage renal disease had a total body clearance of 0.105±0.052L/kg/min.8

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

The oral LD50 in rats is 81mg/kg and in mice is 27mg/kg.12 The intraperitoneal LD50 in rats is 40mg/kg and in mice is 70mg/kg.12

Patients experiencing an overdose may present with sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, and bradycardia.11,13,14 Hemodialysis is not expected to be useful in the treatment of misoprostol overdose13 but oral activated charcoal may help reduce absorption.14 In the event of an overdose, treat symptoms with supportive therapy.13 This may include removal of undissolved tablets from the vagina or buccal cavity, intravenous fluid replacement, acetaminophen, diazepam, haloperidol, or intramuscular diclofenac depending on the symptoms that present.11

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CarbetocinThe risk or severity of adverse effects can be increased when Misoprostol is combined with Carbetocin.
Carboprost tromethamineCarboprost tromethamine may increase the uterotonic activities of Misoprostol.
HydrotalciteThe risk or severity of adverse effects can be increased when Hydrotalcite is combined with Misoprostol.
MagaldrateThe risk or severity of adverse effects can be increased when Magaldrate is combined with Misoprostol.
MagnesiumThe risk or severity of adverse effects can be increased when Magnesium is combined with Misoprostol.
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Misoprostol.
Magnesium chlorideThe risk or severity of adverse effects can be increased when Magnesium chloride is combined with Misoprostol.
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Misoprostol.
Magnesium gluconateThe risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Misoprostol.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Misoprostol.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take with food. Food decreases incidence of diarrhea.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Images
International/Other Brands
Isprelor
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CytotecTablet200 ug/1OralA S Medication Solutions1986-12-27Not applicableUS flag
CytotecTablet200 ug/1OralG.D. Searle LLC Division of Pfizer Inc1986-12-27Not applicableUS flag
CytotecTablet200 ug/1OralApotheca, Inc.2010-01-01Not applicableUS flag
CytotecTablet200 ug/1OralCardinal Health1988-12-272015-12-31US flag
CytotecTablet100 ug/1OralPD-Rx Pharmaceuticals, Inc.1986-12-27Not applicableUS flag
CytotecTablet100 ug/1OralCardinal Health1988-12-272015-12-31US flag
CytotecTablet100 ug/1OralPhysicians Total Care, Inc.1996-07-02Not applicableUS flag
CytotecTablet100 ug/1OralG.D. Searle LLC Division of Pfizer Inc1986-12-27Not applicableUS flag
Cytotec 100 McgTabletOralPfizer Canada Ulc1989-12-312004-07-26Canada flag
Cytotec 200 McgTabletOralPfizer Canada Ulc1986-12-312005-08-05Canada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MisoprostolTablet200 ug/1OralCadila Healthcare Limited2020-01-14Not applicableUS flag
MisoprostolTablet200 ug/1OralReady Meds2012-07-25Not applicableUS flag43386 0161 06 nlmimage10 0b3c05c0
MisoprostolTablet100 ug/1OralAmerican Health Packaging2013-07-08Not applicableUS flag
MisoprostolTablet200 ug/1OralPd Rx Pharmaceuticals, Inc.2012-07-252017-11-20US flag
MisoprostolTablet200 ug/1OralGen Bio Pro Inc2013-01-02Not applicableUS flag
MisoprostolTablet200 ug/1OralNovel Laboratories, Inc.2012-07-25Not applicableUS flag
MisoprostolTablet100 ug/1OralPD-Rx Pharmaceuticals, Inc.2009-12-27Not applicableUS flag
MisoprostolTablet100 ug/1OralLupin Pharmaceuticals,Inc.2012-07-25Not applicableUS flag
MisoprostolTablet200 ug/1OralPharmacist Pharmaceutical, LLC2013-04-12Not applicableUS flag
MisoprostolTablet200 ug/1Oralbryant ranch prepack2002-07-102018-01-31US flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Act Diclo-misoMisoprostol (200 mcg) + Diclofenac sodium (50 mg)Tablet, delayed releaseOralActavis Pharma Company2013-03-272019-08-08Canada flag
Act Diclo-misoMisoprostol (200 mcg) + Diclofenac sodium (75 mg)Tablet, delayed releaseOralActavis Pharma Company2013-03-272019-08-08Canada flag
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralStat Rx USA1997-12-24Not applicableUS flag
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralRebel Distributors1997-12-24Not applicableUS flag
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-232019-10-11US flag
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralPfizer Laboratories Div Pfizer Inc1997-12-24Not applicableUS flag00025 1421 60 nlmimage10 ca12e557
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2004-12-28Not applicableUS flag54868 416520180907 15195 1jambru
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (50 mg/1)Tablet, film coatedOralPD-Rx Pharmaceuticals, Inc.1997-12-242019-09-12US flag
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralA-S Medication Solutions1997-12-24Not applicableUS flag54569 457920180907 15195 1f77log
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (50 mg/1)Tablet, film coatedOralPfizer Laboratories Div Pfizer Inc1997-12-24Not applicableUS flag00025 1411 60 nlmimage10 c812e407

Categories

ATC Codes
G02AD06 — MisoprostolA02BB01 — MisoprostolM01AE56 — Naproxen and misoprostol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Fatty acid methyl esters / Cyclopentanols / Tertiary alcohols / Methyl esters / Cyclic ketones / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic homomonocyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic alcohol / Cyclic ketone / Cyclopentanol / Fatty acid ester / Fatty acid methyl ester
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
0E43V0BB57
CAS number
59122-46-2
InChI Key
OJLOPKGSLYJEMD-URPKTTJQSA-N
InChI
InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
IUPAC Name
methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate
SMILES
CCCCC(C)(O)C\C=C\[[email protected]]1[[email protected]](O)CC(=O)[[email protected]@H]1CCCCCCC(=O)OC

References

Synthesis Reference

Salah Ahmed, Raj Mahajan, "Vaginal tablets comprising misoprostol and methods of making and using the same." U.S. Patent US20070071814, issued March 29, 2007.

US20070071814
General References
  1. Schoenhard G, Oppermann J, Kohn FE: Metabolism and pharmacokinetic studies of misoprostol. Dig Dis Sci. 1985 Nov;30(11 Suppl):126S-128S. doi: 10.1007/bf01309397. [PubMed:3932043]
  2. Turner JV, Agatonovic-Kustrn S, Ward H: Off-label use of misoprostol in gynaecology. Facts Views Vis Obgyn. 2015 Dec 28;7(4):261-264. [PubMed:27729972]
  3. Krugh M, Maani CV: Misoprostol . [PubMed:30969695]
  4. Speer L: Misoprostol Alone is Associated with High Rate of Successful First-Trimester Abortion. Am Fam Physician. 2019 Jul 15;100(2):119. [PubMed:31305043]
  5. Frye LJ, Byrne ME, Winikoff B: A crossover pharmacokinetic study of misoprostol by the oral, sublingual and buccal routes. Eur J Contracept Reprod Health Care. 2016 Aug;21(4):265-8. doi: 10.3109/13625187.2016.1168799. Epub 2016 Apr 22. [PubMed:27102981]
  6. Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V: Rates of serious infection after changes in regimens for medical abortion. N Engl J Med. 2009 Jul 9;361(2):145-51. doi: 10.1056/NEJMoa0809146. [PubMed:19587339]
  7. Tang OS, Gemzell-Danielsson K, Ho PC: Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007 Dec;99 Suppl 2:S160-7. doi: 10.1016/j.ijgo.2007.09.004. Epub 2007 Oct 26. [PubMed:17963768]
  8. Foote EF, Lee DR, Karim A, Keane WF, Halstenson CE: Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function. J Clin Pharmacol. 1995 Apr;35(4):384-9. [PubMed:7650228]
  9. Cook CS, Schoenhard GL, Karim A: Effect of salicylic acid on the plasma protein binding and pharmacokinetics of misoprostol acid. J Pharm Sci. 1994 Jun;83(6):883-6. doi: 10.1002/jps.2600830625. [PubMed:9120826]
  10. Hobday K, Hulme J, Homer C, Zualo Wate P, Belton S, Prata N: "My job is to get pregnant women to the hospital": a qualitative study of the role of traditional birth attendants in the distribution of misoprostol to prevent post-partum haemorrhage in two provinces in Mozambique. Reprod Health. 2018 Oct 16;15(1):174. doi: 10.1186/s12978-018-0622-4. [PubMed:30326927]
  11. Barros JG, Reis I, Graca LM: Acute misoprostol toxicity during the first trimester of pregnancy. Int J Gynaecol Obstet. 2011 May;113(2):157-8. doi: 10.1016/j.ijgo.2010.12.006. Epub 2011 Feb 22. [PubMed:21333990]
  12. Cayman Chemicals: Misoprostol MSDS [Link]
  13. FDA Approved Drug Products: Misoprostol Tablets [Link]
  14. FDA Approved Drug Products: Misoprostol and Diclofenac Tablets [Link]
Human Metabolome Database
HMDB0015064
KEGG Drug
D00419
PubChem Compound
5282381
PubChem Substance
46505041
ChemSpider
4445541
BindingDB
85606
RxNav
42331
ChEBI
63610
ChEMBL
CHEMBL606
Therapeutic Targets Database
DAP000358
PharmGKB
PA450523
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Misoprostol
AHFS Codes
  • 56:28.28 — Prostaglandins
FDA label
Download (246 KB)
MSDS
Download (147 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedHealth Services ResearchAbortion, Therapeutic1
4CompletedHealth Services ResearchMenstrual Regulation1
4CompletedOtherContraceptive Device; Complications1
4CompletedPreventionBleeding During Myomectomy1
4CompletedPreventionHemorrhage1
4CompletedPreventionIntra-uterine Device Complication1
4CompletedPreventionNSAID-associated Gastroduodenal Injury1
4CompletedPreventionPostpartum Haemorrhage (PPH)4
4CompletedPreventionPostpartum Haemorrhage (PPH) / Intrapartum Haemorrhage1
4CompletedPreventionProstaglandin E2 "Misoprostol" Prior Abdominal Myomectomy1

Pharmacoeconomics

Manufacturers
  • Gd searle llc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Packagers
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Cardinal Health
  • Chirogate International Inc.
  • Direct Dispensing Inc.
  • DispenseXpress Inc.
  • Dispensing Solutions
  • GD Searle LLC
  • Greenstone LLC
  • H.J. Harkins Co. Inc.
  • Hawkins Inc.
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Neuman Distributors Inc.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmacia Inc.
  • Physicians Total Care Inc.
  • Piramal Healthcare
  • Rebel Distributors Corp.
  • Southwood Pharmaceuticals
Dosage Forms
FormRouteStrength
Tablet, film coatedOral
TabletOral75 mg
Tablet, delayed releaseOral75 mg
TabletVaginal200 mg
TabletVaginal50 cg
TabletOral200 mcg
Tablet, orally disintegratingOral400 mcg
GelVaginal25 mcg/300mcg
TabletOral100 ug/1
TabletOral200 ug/1
TabletOral400 MCG
TabletOral
Tablet200 mcg
Tablet, delayed releaseOral
TabletOral50 mg
TabletVaginal200 mcg
Tablet200 mg
Kit; tabletBuccal; Oral
Tablet400 MICROGRAMMI
TabletOral100 mcg
Drug delivery systemVaginal200 mcg
Tablet
TabletOral
Tablet400 Mikrogramm
Prices
Unit descriptionCostUnit
Misoprostol hpmc powder152.0USD g
Cytotec 60 200 mcg tablet Bottle121.93USD bottle
Cytotec 60 100 mcg tablet Bottle81.36USD bottle
Arthrotec 75 tablet ec4.07USD tablet
Arthrotec ec 50 mg-200 mcg tablet2.99USD tablet
Arthrotec ec 75 mg-200 mcg tablet2.99USD tablet
Arthrotec ec 75 tablet2.96USD tablet
Arthrotec 75 75-200 mg-mcg tablet2.82USD tablet
Arthrotec 50 50-200 mg-mcg tablet2.7USD tablet
Cytotec 200 mcg tablet1.95USD tablet
Cytotec 100 mcg tablet1.34USD tablet
Misoprostol 200 mcg tablet1.22USD tablet
Misoprostol 100 mcg tablet0.84USD tablet
Apo-Misoprostol 200 mcg Tablet0.45USD tablet
Apo-Misoprostol 100 mcg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5601843No1997-02-112014-02-11US flag
US5698225No1997-12-162010-05-03US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)261-263http://www.chemspider.com/Chemical-Structure.4445541.html
water solubility1.6mg/mLhttps://www.caymanchem.com/pdfs/13820.pdf
Predicted Properties
PropertyValueSource
Water Solubility0.0164 mg/mLALOGPS
logP3.88ALOGPS
logP3.86ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)14.68ChemAxon
pKa (Strongest Basic)-0.95ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.83 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity107.88 m3·mol-1ChemAxon
Polarizability45.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier+0.938
Caco-2 permeable-0.5339
P-glycoprotein substrateSubstrate0.6607
P-glycoprotein inhibitor INon-inhibitor0.7261
P-glycoprotein inhibitor IIInhibitor0.6504
Renal organic cation transporterNon-inhibitor0.9146
CYP450 2C9 substrateNon-substrate0.857
CYP450 2D6 substrateNon-substrate0.9024
CYP450 3A4 substrateSubstrate0.6281
CYP450 1A2 substrateNon-inhibitor0.8358
CYP450 2C9 inhibitorNon-inhibitor0.8175
CYP450 2D6 inhibitorNon-inhibitor0.9459
CYP450 2C19 inhibitorNon-inhibitor0.8199
CYP450 3A4 inhibitorNon-inhibitor0.795
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9591
Ames testNon AMES toxic0.8289
CarcinogenicityNon-carcinogens0.8941
BiodegradationNot ready biodegradable0.8797
Rat acute toxicity3.7051 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.964
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Rna polymerase ii transcription factor activity, ligand-activated sequence-specific dna binding
Specific Function
Receptor for prostaglandin E2 (PGE2); the EP3 receptor may be involved in inhibition of gastric acid secretion, modulation of neurotransmitter release in central and peripheral neurons, inhibition ...
Gene Name
PTGER3
Uniprot ID
P43115
Uniprot Name
Prostaglandin E2 receptor EP3 subtype
Molecular Weight
43309.335 Da
References
  1. Nakae K, Hayashi F, Hayashi M, Yamamoto N, Iino T, Yoshikawa S, Gupta J: Functional role of prostacyclin receptor in rat dorsal root ganglion neurons. Neurosci Lett. 2005 Nov 18;388(3):132-7. [PubMed:16039053]
  2. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20. [PubMed:18472336]
  3. Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. [PubMed:12097143]
  4. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [PubMed:9313928]
  5. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001 Oct;108(8):1229-35. [PubMed:11602631]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Prostaglandin e receptor activity
Specific Function
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the ...
Gene Name
PTGER2
Uniprot ID
P43116
Uniprot Name
Prostaglandin E2 receptor EP2 subtype
Molecular Weight
39759.945 Da
References
  1. Nakae K, Hayashi F, Hayashi M, Yamamoto N, Iino T, Yoshikawa S, Gupta J: Functional role of prostacyclin receptor in rat dorsal root ganglion neurons. Neurosci Lett. 2005 Nov 18;388(3):132-7. [PubMed:16039053]
  2. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20. [PubMed:18472336]
  3. Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. [PubMed:12097143]
  4. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [PubMed:9313928]
  5. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001 Oct;108(8):1229-35. [PubMed:11602631]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Agonist
General Function
Prostaglandin e receptor activity
Specific Function
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role...
Gene Name
PTGER4
Uniprot ID
P35408
Uniprot Name
Prostaglandin E2 receptor EP4 subtype
Molecular Weight
53118.845 Da
References
  1. Nakae K, Hayashi F, Hayashi M, Yamamoto N, Iino T, Yoshikawa S, Gupta J: Functional role of prostacyclin receptor in rat dorsal root ganglion neurons. Neurosci Lett. 2005 Nov 18;388(3):132-7. [PubMed:16039053]
  2. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20. [PubMed:18472336]
  3. Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. [PubMed:12097143]
  4. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [PubMed:9313928]
  5. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001 Oct;108(8):1229-35. [PubMed:11602631]
  6. Crider JY, Xu SX, Sharif NA: Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: comparison with binding data from human platelets. Prostaglandins Leukot Essent Fatty Acids. 2001 Nov-Dec;65(5-6):253-8. [PubMed:11993717]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Prostaglandin e receptor activity
Specific Function
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an importa...
Gene Name
PTGER1
Uniprot ID
P34995
Uniprot Name
Prostaglandin E2 receptor EP1 subtype
Molecular Weight
41800.655 Da
References
  1. Krugh M, Maani CV: Misoprostol . [PubMed:30969695]

Drug created on June 13, 2005 07:24 / Updated on October 29, 2020 19:26

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates